{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:12:21Z","timestamp":1791180741441,"version":"4.1.0"},"reference-count":52,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,4,20]],"date-time":"2009-04-20T00:00:00Z","timestamp":1240185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:p>Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma. HCV is endemic in most parts of the world, with an estimated 170 million people infected worldwide and 3\u20134 million new cases each year. HCV\u2010related end\u2010stage liver disease is now the main indication for liver transplantation in the USA and Western Europe. Unfortunately, no vaccine or immunoglobulin is available to prevent HCV infection. Currently, HCV treatment consists of the combined administration of pegylated interferon and ribavirin for a period of 24\u201348\u00a0weeks, resulting in complete viral eradication in 40\u201380% of patients, depending on genotype, viral load and patient characteristics. This therapy is often accompanied with side\u2010effects that affect compliance and reduce treatment outcomes.<\/jats:p><jats:p>Recently, reliable<jats:italic>in vitro<\/jats:italic>culture systems have been developed which accelerated antiviral therapy research. Many new specifically targeted antiviral therapies for hepatitis C (STAT\u2010C) and treatment strategies are evaluated in clinical trials. These new antiviral agents are expected to improve treatment significantly with potentially shorter treatment duration. The most promising antiviral agents will be reviewed.<\/jats:p>","DOI":"10.1111\/j.1423-0410.2009.01187.x","type":"journal-article","created":{"date-parts":[[2009,4,20]],"date-time":"2009-04-20T08:14:50Z","timestamp":1240215290000},"page":"1-12","source":"Crossref","is-referenced-by-count":10,"title":["New developments in the antiviral treatment\u00a0of hepatitis\u00a0C"],"prefix":"10.1111","volume":"97","author":[{"given":"J.","family":"De Bruijne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. J.","family":"Weegink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. L. M.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. W.","family":"Reesink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,6,7]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2523562"},{"key":"e_1_2_9_3_2","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff LB","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70216-4"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107053450107"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.05.013"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198612183152503"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04082"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"e_1_2_9_13_2","first-page":"801","article-title":"Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model\u2010based regional estimates","volume":"77","author":"Kane A","year":"1999","journal-title":"Bull World Health Organ"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2002.00329.x"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(02)80076-7"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.07.033"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.07.003"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20819"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-9506"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04077"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1114016"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5424.110"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.02.037"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20405"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20876"},{"key":"e_1_2_9_26_2","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1177\/135965350400900612","article-title":"Virological effects of ISIS 14\u00a0803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment","volume":"9","author":"Soler M","year":"2004","journal-title":"Antivir Ther"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature02099"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2260-2266.2004"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.07.013"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21774"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.05.004"},{"key":"e_1_2_9_32_2","doi-asserted-by":"crossref","unstructured":"McHutchisonJG EversonGT GordonSC JacobsonI KauffmanR McNairL MuirAJ PROVE1: Results from a phase 2 study of telaprevir with Peginterferon alfa\u20102a and ribavirin in treatment\u2010na\u00efve subjects with hepatitis C.Presented at the 41st Annual Meeting of the European Association for the Study of the LiverApril 23\u201327 2008; Milan Italy.","DOI":"10.1016\/S0168-8278(08)60006-9"},{"key":"e_1_2_9_33_2","unstructured":"ZeuzemS HezodeC FerenciP DusheikoGM AlvesK BengtssonL GharakhanianS KauffmanR AlamJ PawlotskyJM:Telaprevir in combination with peginterferon\u2010alfa\u20102a with or without ribavirin in the treatment of chronic hepatitis C: final results of the PROVE2 study.Presented at the 59th Annual Meeting of the American Association for the Study of Liver DiseasesOctober 31\u2013November 4 2008; San Francisco CA."},{"key":"e_1_2_9_34_2","unstructured":"MchutchisonJG ShiffmanM TerraultN MannsMP DiBA JacobsonI AfdhalNH HeathcoteEJ ZeuzemS ReesinkH GeorgeS AddaN MuirAJ:A phase 2b study of telaprevir with peginterferon\u2010alfa\u20102a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon\u2010alfa\u20102a\/b and ribavirin therapy: PROVE3 interim results.Presented at the 59th Annual Meeting of the American Association for the Study of Liver DiseasesOctober 31\u2013November 4 2008; San Francisco CA."},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.01.041"},{"key":"e_1_2_9_36_2","unstructured":"KwoP LawitzE McConeJ SchiffER VierlingJM PoundD DavisM GalatiJS GordonSC RavendhranN RossaroL AndersonFH JacobsonI RubinR KouryK ChaudhriEI AlbrechtJK:HCV SPRINT\u20101: boceprevir plus peginterferon\u2010alfa\u20102b\/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients.Presented at the 59th Annual Meeting of the American Association for the Study of Liver DiseasesOctober 31\u2013November 4 2008; San Francisco CA."},{"key":"e_1_2_9_37_2","unstructured":"SchiffER PoordadF JacobsonI FlammS BaconB LawitzE GordonSC MchutchisonJG GhalibR PoynardT SulkowskiM TrepoC RizzettoM ZeuzemS MarcellinP MendezP BrassC AlbrechtJK:Boceprevir (B) combination therapy in null responders (NR): Response dependent on interferon responsiveness.Presented at the 41st Annual Meeting of the European Association for the Study of the LiverApril 23\u201327 2008; Milan Italy."},{"key":"e_1_2_9_38_2","unstructured":"ReesinkH VerloesR Abou FarhaK Van VlietA WeeginkC Van't KloosterG AharchiF MarienK Van RemoortereP De KockH BroeckaertF FanningG MeyvischP Van BeirendonckE SimmenK:Safety of the HCV protease inhibitor TMC435350 in healthy volunteers and safety and activity in chronic hepatitis C infected individuals: A phase 1 study.Presented at the 41st Annual Meeting of the European Association for the Study of the LiverApril 23\u201327 2008; Milan Italy."},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22321"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22357"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22593"},{"key":"e_1_2_9_42_2","unstructured":"ReddyR Rodriguez\u2010TorresM GaneE RobsonR LalezariJ EversonGT DeJesusE MchutchisonJG VargasHE BeardA RodriguezCA HillG SymondsW BerreyM:Antiviral activity pharmacokinetics safety and tolerability of R7128 a novel nucleoside HCV RNA polymerase inhibitor following multiple ascending oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy.Presented at the 57th Annual Meeting of the American Association for the Study of Liver DiseasesOctober 27\u201331 2006 Boston MA."},{"key":"e_1_2_9_43_2","unstructured":"GaneE Rodriguez\u2010TorresM NelsonD JacobsonI MchutchisonJG JeffersL BeardA WalkerS ShulmanN SymondsW AlbanisE BerreyM:Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non\u2010responders: interim results of R7128 1500\u00a0mg bid with peg\u2010IFN and ribavirin for 28 days.Presented at the 59th Annual Meeting of the American Association for the Study of Liver DiseasesOctober 31\u2013November 4 2008; San Francisco CA."},{"key":"e_1_2_9_44_2","doi-asserted-by":"crossref","unstructured":"StandringDN LanfordR Cretton\u2010ScottE LickliderL LarssonM PierraC GosselinG PerigaudC SurlerauxD MayesB MoussaA SeldenJ:Potent antiviral activity of second generation nucleoside inhibitors IDX102 and IDX 184 in HCV\u2010infected chimpanzees.Presented at the 41st Annual Meeting of the European Association for the Study of the LiverApril 23\u201327 2008; Milan Italy.","DOI":"10.1016\/S0168-8278(08)60069-0"},{"key":"e_1_2_9_45_2","doi-asserted-by":"crossref","unstructured":"NicolasO BoivinI BedardJ:Genotypic analysis of HCV NS5B variants selected from patients treated with VCH\u2010759.Presented at the 41st Annual Meeting of the European Association for the Study of the LiverApril 23\u201327 2008; Milan Italy.","DOI":"10.1016\/S0168-8278(08)60846-6"},{"key":"e_1_2_9_46_2","unstructured":"NettlesR ChienC PerssonA Min Gao BelemaM MeanwellNA DeMiccoM MarburyTC GoldwaterR NorthupP CoumbisJ KraftWK CharltonM Lopez\u2010TalaveraJC GraselaD:BMS\u2010790052 is a first\u2010in\u2010class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: Results from a proof\u2010of\u2010concept study.Presented at the 59th Annual Meeting of the American Association for the Study of Liver DiseasesOctober 31\u2013November 4 2008 San Francisco CA."},{"key":"e_1_2_9_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22131"},{"key":"e_1_2_9_48_2","doi-asserted-by":"crossref","unstructured":"FlisiakR FeinmanSV JablowskiM HorbanA KryczkaW HalotaW HeathcoteJE MazzellaG VandelliC LizJS CrabbzR ScalfaroP PorchetH:Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon alpha\u20102a in treatment na\u00efve chronic HCV patients.Presented at the 41st Annual Meeting of the European Association for the Study of the LiverApril 23\u201327 2008; Milan Italy.","DOI":"10.1016\/S0168-8278(08)60145-2"},{"key":"e_1_2_9_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03781.x"},{"key":"e_1_2_9_50_2","doi-asserted-by":"crossref","unstructured":"RossignolJF ElfertA El\u2010GoharyY KeeffeEB:Randomized controlled trial of nitazoxanide\u2010peginterferon\u2010ribavirin nitazoxanide\u2010peginterferon and peginterferon\u2010ribavirin in the treatment of patients with chronic hepatitis C genotype 4.Presented at the 41st Annual Meeting of the European Association for the Study of the LiverApril 23\u201327 2008; Milan Italy.","DOI":"10.1016\/S0168-8278(08)60070-7"},{"key":"e_1_2_9_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21773"},{"key":"e_1_2_9_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20839"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.02.018"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1423-0410.2009.01187.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1423-0410.2009.01187.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T02:29:21Z","timestamp":1739068161000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1423-0410.2009.01187.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,7]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1111\/j.1423-0410.2009.01187.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1423-0410.2009.01187.x","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,7]]}}}